Dr. Dave Weldon, Trump’s CDC Pick, Wasn’t on Anyone’s Radar

But over the years, the former congressman’s views have often aligned with those of his potential boss, Robert F. Kennedy Jr. — particularly on vaccine safety.Dr. Dave Weldon, a former Republican congressman who is President-elect Donald J. Trump’s pick to lead the Centers for Disease Control and Prevention, has been off the political stage for more than 15 years.Now running a private medical practice in Malabar, Fla., Mr. Weldon was hardly regarded as a leading candidate to run the federal agency, a $9 billion behemoth with a staff of more than 13,000 that has become a locus of conservative rage.Yet over the years his views have aligned in many ways with those of Robert F. Kennedy Jr., Mr. Trump’s choice for health and human services secretary, and Dr. Weldon’s potential boss. The two have maintained a 25-year relationship.Like Mr. Kennedy, Dr. Weldon, 71, has claimed that some children may develop autism when vaccinated against measles because of genetics or other factors, despite dozens of robust studies that thoroughly disproved the claim.Reached by phone on Tuesday, he declined to say whether he still held those beliefs and added that he could not yet comment on “anything of substance.”Dr. Weldon said that in his time in the House of Representatives, he worked with Mr. Kennedy “to get the mercury out of the childhood vaccines.” Still, he described himself as a supporter of vaccination.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe.

Read more →

Boosters for Moderna and J.&J. Recipients Not Up for Debate at C.D.C. Panel

A committee of scientific advisers to the Centers for Disease Control and Prevention voted on Thursday to recommend booster doses of the Pfizer-BioNTech coronavirus vaccine to many Americans who were fully inoculated with the same vaccine. The panel advised that those booster shots go to older Americans and people with certain medical conditions, but excluded those at risk because of their jobs.But the panel was not asked to judge whether people who received the Moderna and Johnson & Johnson vaccines should receive Pfizer boosters. The Food and Drug Administration is reviewing data for a Moderna booster, but has not received an application from Johnson & Johnson for a booster of its vaccine.Several experts nevertheless supported a mix-and-match strategy, and signaled that they would revisit the issue as new data emerge.The advisers wrestled with the practicalities of endorsing a booster shot of Pfizer’s vaccine, but not the other two. Recipients of those vaccines may rightly feel resentful of being asked to wait if the evidence suggests they need boosters, they noted.“I just don’t understand how, later this afternoon, we can say to people 65 and older, ‘You’re at risk for severe disease and death, but only half of you can protect yourselves right now,’” said Dr. Sarah Long, a pediatrician and infectious diseases expert at Drexel University College of Medicine in Pennsylvania.“It might be the right thing to do,” she said. “It just doesn’t sound like a good public health policy.”Some experts seemed to suggest on Wednesday that it might be better to hold off on recommending any booster shots until recipients of all three vaccines could qualify for them.Moderna’s authorization may arrive in a few days, or weeks. The company has applied for authorization of a booster carrying half the dosage given in the first two shots, which has delayed the F.D.A.’s deliberations.Federal regulators have indicated that there was insufficient evidence for mixing first shots of the Moderna vaccine with a Pfizer booster, or vice versa.

Read more →

Federal Panel Recommends Booster Shots, Opening New Campaign Against the Virus

Scientific advisers to the C.D.C. endorsed additional doses of the Pfizer-BioNTech vaccine for older Americans but not for health care workers, in a possible rift with regulators.An influential scientific panel on Thursday opened a new front in the campaign against the coronavirus, recommending booster shots of the Pfizer-BioNTech Covid vaccine for a wide range of Americans, including tens of millions of older people. But the experts declined to endorse additional doses for health care workers, teachers and others who might have higher exposure on the job.The decisions were made by the C.D.C. panel, the Advisory Committee on Immunization Practices, in a series of votes, during which scientists agonized over their choices. The recommendations revealed deep divisions among federal regulators and outside advisers about how to contain the virus nearly two years into the pandemic.Just a day earlier, the Food and Drug Administration authorized booster shots for certain frontline workers. But the C.D.C.’s advisers disagreed that the doses were needed by so many healthy people.The next step is for Dr. Rochelle Walensky, the director of the C.D.C., to make a formal recommendation. If she follows the guidance of the agency’s advisory committee, as is typically the case, the agency’s guidance may conflict with that of the F.D.A.One administration official said Xavier Becerra, the secretary of health and human services, might ultimately have to mediate between the two agencies.“There’s a complexity here, because Dr. Walensky was part of the White House announcement” on boosters, said Dr. Ashish Jha, dean of the Brown University School of Global Health. “I think she’s going to feel some amount of pressure to authorize this for health care workers.”Depending on what is decided, the White House is likely to begin promoting and rolling out a plan for booster shots as soon as Friday. That would be in keeping with the administration’s previously announced plan to offer the additional doses the week of Sept. 20.Whatever the scientific reservations, millions are expected to seek out booster shots. In one recent poll, about three-quarters of vaccinated Americans said they would opt for a booster if the doses were available.State health departments generally follow the recommendations of the C.D.C. But many Americans were scrambling for boosters even before the F.D.A.’s authorization, typically by finding a cooperative pharmacist or by claiming to be unvaccinated.The C.D.C.’s advisers acted on what they described — with considerable frustration — as scant research, mulling over conflicting data points that seldom pointed in one direction.In the end, the panel unanimously endorsed booster shots for adults over 65 and for residents of long-term care facilities, who most clearly will benefit.The committee also backed the shots for people 50 to 64 with medical conditions that leave them at risk for severe Covid-19, as well as those 18 to 49 who have certain medical conditions, based on an assessment of their individual needs.Only Americans who already have received two doses of the Pfizer-BioNTech vaccine will qualify for booster shots. The panel was not asked to judge whether people who received the Moderna and Johnson & Johnson vaccines should receive the additional doses, which have not been authorized by the F.D.A.Several experts on the C.D.C. panel nevertheless urged a mix-and-match strategy, saying that they could see little reason not to offer a Pfizer-BioNTech booster to someone who qualified but had received, for example, the J. & J. vaccine. Some members warned that delivering multiple rounds of booster shots, available periodically when authorized, would tax an already burdened health care system.The C.D.C. panel’s guidance followed weeks of internal disagreement and public debate among American health officials and advisers. In mid-August, President Biden announced plans for a booster rollout, but scientists and regulators were quick to point out there was little research on who might benefit and how the doses should be distributed.The F.D.A.’s acting commissioner, Janet Woodcock, said on Wednesday that the agency’s authorization would allow for booster doses “in certain populations such as health care workers, teachers and day care staff, grocery workers and those in homeless shelters or prisons, among others.”But some members of the committee said there was little evidence to suggest that vaccinated teachers, and even health care workers, were at risk of repeated exposure to the virus. The decision reflected fears that such a broad recommendation would effectively throw the doors open to an all-adults booster campaign.“My sense was that the committee felt that that was sort of a hole that you could drive a truck through,” Dr. Paul Offit, a professor at the University of Pennsylvania and a member of the F.D.A.’s vaccine advisory panel, told reporters at an online briefing on Thursday.Over the two days, the panel wrestled with the public’s expectations for Covid vaccines, the safety of third doses and how a booster program would affect nursing home residents. Booster doses alone would not turn back the pandemic, some scientists noted: Only vaccinating the unvaccinated would do that..css-1xzcza9{list-style-type:disc;padding-inline-start:1em;}.css-3btd0c{font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:1rem;line-height:1.375rem;color:#333;margin-bottom:0.78125rem;}@media (min-width:740px){.css-3btd0c{font-size:1.0625rem;line-height:1.5rem;margin-bottom:0.9375rem;}}.css-3btd0c strong{font-weight:600;}.css-3btd0c em{font-style:italic;}.css-w739ur{margin:0 auto 5px;font-family:nyt-franklin,helvetica,arial,sans-serif;font-weight:700;font-size:1.125rem;line-height:1.3125rem;color:#121212;}#NYT_BELOW_MAIN_CONTENT_REGION .css-w739ur{font-family:nyt-cheltenham,georgia,’times new roman’,times,serif;font-weight:700;font-size:1.375rem;line-height:1.625rem;}@media (min-width:740px){#NYT_BELOW_MAIN_CONTENT_REGION .css-w739ur{font-size:1.6875rem;line-height:1.875rem;}}@media (min-width:740px){.css-w739ur{font-size:1.25rem;line-height:1.4375rem;}}.css-9s9ecg{margin-bottom:15px;}.css-16ed7iq{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;padding:10px 0;background-color:white;}.css-pmm6ed{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;}.css-pmm6ed > :not(:first-child){margin-left:5px;}.css-5gimkt{font-family:nyt-franklin,helvetica,arial,sans-serif;font-size:0.8125rem;font-weight:700;-webkit-letter-spacing:0.03em;-moz-letter-spacing:0.03em;-ms-letter-spacing:0.03em;letter-spacing:0.03em;text-transform:uppercase;color:#333;}.css-5gimkt:after{content:’Collapse’;}.css-rdoyk0{-webkit-transition:all 0.5s ease;transition:all 0.5s ease;-webkit-transform:rotate(180deg);-ms-transform:rotate(180deg);transform:rotate(180deg);}.css-eb027h{max-height:5000px;-webkit-transition:max-height 0.5s ease;transition:max-height 0.5s ease;}.css-6mllg9{-webkit-transition:all 0.5s ease;transition:all 0.5s ease;position:relative;opacity:0;}.css-6mllg9:before{content:”;background-image:linear-gradient(180deg,transparent,#ffffff);background-image:-webkit-linear-gradient(270deg,rgba(255,255,255,0),#ffffff);height:80px;width:100%;position:absolute;bottom:0px;pointer-events:none;}.css-uf1ume{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-webkit-justify-content:space-between;-ms-flex-pack:justify;justify-content:space-between;}.css-wxi1cx{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-align-self:flex-end;-ms-flex-item-align:end;align-self:flex-end;}.css-12vbvwq{background-color:white;border:1px solid #e2e2e2;width:calc(100% – 40px);max-width:600px;margin:1.5rem auto 1.9rem;padding:15px;box-sizing:border-box;}@media (min-width:740px){.css-12vbvwq{padding:20px;width:100%;}}.css-12vbvwq:focus{outline:1px solid #e2e2e2;}#NYT_BELOW_MAIN_CONTENT_REGION .css-12vbvwq{border:none;padding:10px 0 0;border-top:2px solid #121212;}.css-12vbvwq[data-truncated] .css-rdoyk0{-webkit-transform:rotate(0deg);-ms-transform:rotate(0deg);transform:rotate(0deg);}.css-12vbvwq[data-truncated] .css-eb027h{max-height:300px;overflow:hidden;-webkit-transition:none;transition:none;}.css-12vbvwq[data-truncated] .css-5gimkt:after{content:’See more’;}.css-12vbvwq[data-truncated] .css-6mllg9{opacity:1;}.css-qjk116{margin:0 auto;overflow:hidden;}.css-qjk116 strong{font-weight:700;}.css-qjk116 em{font-style:italic;}.css-qjk116 a{color:#326891;-webkit-text-decoration:underline;text-decoration:underline;text-underline-offset:1px;-webkit-text-decoration-thickness:1px;text-decoration-thickness:1px;-webkit-text-decoration-color:#326891;text-decoration-color:#326891;}.css-qjk116 a:visited{color:#326891;-webkit-text-decoration-color:#326891;text-decoration-color:#326891;}.css-qjk116 a:hover{-webkit-text-decoration:none;text-decoration:none;}“We may move the needle a little bit by giving a booster dose to people,” said Dr. Helen Talbot, an associate professor of medicine at Vanderbilt University. But, she added, “the hospitals are full because people are not vaccinated.”The advisers also grappled with a lack of clarity on the goal of the vaccines: Should it be to prevent all infections, or to forestall severe illness and hospitalization?Many suggested that booster doses could do only the latter, and that trying to thwart all infections was impossible. That reasoning supported limiting who should receive the doses, the experts said.On Thursday, C.D.C. scientists presented models indicating that, if booster doses were to slightly increase people’s protection against hospitalization, the additional shots could prevent more than 2,000 hospitalizations for every million doses given.But it was not clear how long additional protection from a booster would last, raising the prospect that boosters would need to be given repeatedly.Boosters can reduce infections in nursing home residents, who are among those at highest risk. Even so, cases in nursing homes will persist when community transmission is high, according to a modeling study presented at the meeting.The advisers also wrestled with the practicalities of endorsing a booster shot for only Pfizer-BioNTech recipients, when close to half of vaccinated Americans have received Moderna or J. & J. vaccines.“I just don’t understand how, later this afternoon, we can say to people 65 and older, ‘You’re at risk for severe disease and death, but only half of you can protect yourselves right now,’” said Dr. Sarah Long, a pediatrician and infectious diseases expert at Drexel University College of Medicine in Pennsylvania.Committee members also expressed concern on Thursday that some recommendations — particularly that certain younger Americans be allowed booster shots after an assessment of individual risks — would mean that only the wealthy and educated would gain access to additional shots.Some experts seemed to suggest on Wednesday that it might be better to hold off on recommending any booster shots until recipients of all three vaccines could qualify for them.Moderna’s booster authorization may arrive in a few days to weeks. The company has applied to the F.D.A. for authorization of a booster shot carrying half the dosage given in the first two shots, which has complicated the agency’s deliberations.Some global health experts have criticized the Biden administration for pushing booster shots when much of the world has yet to receive a first dose. But analysts noted that even if the United States distributes booster shots, there should still be considerable excess vaccine supply this year, and they urged the government to begin sending the extra doses abroad.Sheryl Stolberg contributed reporting from Washington.

Read more →

Virus Variants Threaten to Draw Out the Pandemic, Scientists Say

Declining infection rates over all masked a rise in more contagious forms of the coronavirus. Vaccines will stop the spread, if Americans postpone celebration just a bit longer.For weeks, the mood in much of the United States has been buoyant. Cases, hospitalizations and deaths from the coronavirus have fallen steeply from their highs, and millions of people are being newly vaccinated every day. Restaurants, shops and schools have reopened. Some states, like Texas and Florida, have abandoned precautions altogether.In measurable ways, Americans are winning the war against the coronavirus. Powerful vaccines and an accelerating rollout all but guarantee an eventual return to normalcy — to backyard barbecues, summer camps and sleepovers.But it is increasingly clear that the next few months will be painful. So-called variants are spreading, carrying mutations that make the coronavirus both more contagious and in some cases more deadly.Even as vaccines were authorized late last year, illuminating a path to the pandemic’s end, variants were trouncing Britain, South Africa and Brazil. New variants have continued to pop up — in California one week, in New York and Oregon the next. As they take root, these new versions of the coronavirus threaten to postpone an end to the pandemic. At the moment, most vaccines appear to be effective against the variants. But public health officials are deeply worried that future iterations of the virus may be more resistant to the immune response, requiring Americans to queue up for regular rounds of booster shots or even new vaccines.“We don’t have evolution on our side,” said Devi Sridhar, a professor of public health at the University of Edinburgh in Scotland. “This pathogen seems to always be changing in a way that makes it harder for us to suppress.”Seniors wait in line to receive vaccinations in Belford Roxo, Brazil. A variant first found in the country has appeared in North America.Dado Galdieri for The New York TimesHealth officials acknowledge an urgent need to track these new viruses as they crawl across the United States. Already, B.1.1.7, the highly contagious variant that walloped Britain and is wreaking havoc in continental Europe, is rising exponentially in the United States.Limited genetic testing has turned up more than 12,500 cases, many in Florida and Michigan. As of March 13, the variant accounted for about 27 percent of new cases nationwide, up from just 1 percent in early February.The Biden administration has pledged a “down payment” of $200 million to ramp up surveillance, an infusion intended to make it possible to analyze 25,000 patient samples each week for virus variants. It’s an ambitious goal: The country was sequencing just a few hundred samples each week in December, then scaling up to about 9,000 per week as of March 27.Until recently, B.1.1.7’s rise was camouflaged by falling rates of infection over all, lulling Americans into a false sense of security and leading to prematurely relaxed restrictions, researchers say.“The best way to think about B.1.1.7 and other variants is to treat them as separate epidemics,” said Sebastian Funk, a professor of infectious disease dynamics at the London School of Hygiene and Tropical Medicine. “We’re really kind of obscuring the view by adding them all up to give an overall number of cases.”Other variants identified in South Africa and Brazil, as well as some virus versions first seen in the United States, have been slower to spread. But they, too, are worrisome, because they contain a mutation that diminishes the vaccines’ effectiveness. Just this week, an outbreak of P.1, the variant that crushed Brazil, forced a shutdown of the Whistler Blackcomb ski resort in British Columbia.A patient brought into the Royal London Hospital in Britain in January. A surge of infections mostly caused by a more contagious variant was difficult to bring under control. Andy Rain/EPA, via ShutterstockThe world is caught in a sprint between vaccines and variants, and the shots eventually will win, scientists say. But because each infection gives the coronavirus a chance to evolve still further, vaccinations in the United States and elsewhere must proceed as fast as possible.Infections are rising again, driven to an uncertain degree by B.1.1.7 and other variants. Earlier this week, Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, pleaded with Americans to continue to practice masking and social distancing, saying she felt a sense of “impending doom.”“We have so much to look forward to — so much promise and potential of where we are and so much reason for hope,” she said. “But right now I’m scared.”‘More infectious for more days’The coronavirus was supposed to be slow to change shape. Like all viruses, it would pick up mutations and evolve into thousands of variants, scientists said at the beginning of the pandemic. But it would not change significantly for years — a stupid virus, some called it.The pathogen defied those predictions. “We expected the virus to change,” said Dr. Michael Diamond, a viral immunologist at Washington University in St. Louis. “We didn’t quite anticipate how quickly it was going to occur.”A variant is of concern only if it is more contagious, causes more severe disease, or blunts the immune response. The variants identified in Britain, South Africa, Brazil and California all fit the criteria.B.1.1.7, the first to come to widespread attention, is about 60 percent more contagious and 67 percent more deadly than the original form of the virus, according to the most recent estimates.The variant is no different from the original in how it spreads, but infected people seem to carry more of the virus and for longer, said Katrina Lythgoe, an evolutionary biologist at the University of Oxford. “You’re more infectious for more days,” she said.So contagious is B.1.1.7 that Britain succeeded in driving down infections only after nearly three months of strict stay-at-home orders, plus an aggressive vaccination program. Even so, cases fell much more slowly than they did during a similar lockdown in March and April.In continental Europe, a wave of B.1.1.7 cases was building for months, mostly unnoticed beneath a steady churn of infections. The variant wave is now cresting.A shopping area in Berlin. Germany’s daily case rate has doubled, triggering a ban on nighttime gatherings in Berlin.Lena Mucha for The New York TimesA doctor vaccinated a staff worker at a hospital in Munich. Much of Europe has been overwhelmed by a more contagious version of the coronavirus called B.1.1.7.Laetitia Vancon for The New York TimesPoland’s rate of daily new cases has quintupled since mid-February, forcing the closure of most public venues. Germany’s has doubled, triggering a ban on nighttime gatherings in Berlin.In France, where B.1.1.7 is causing three-quarters of new infections, some hospitals have had to move coronavirus patients to Belgium to free up beds. Roughly as many people are dying each day from Covid-19 in Europe as were this time a year ago.For too long, government officials disregarded the threat. “Case plateaus can hide the emergence of new variants,” said Carl Pearson, a research fellow at the London School of Hygiene and Tropical Medicine. “And the higher those plateaus are, the worse the problem is.”In the United States, coronavirus infections began a rapid decline in January, soon prompting many state leaders to reopen businesses and ease restrictions. But scientists repeatedly warned that the drop would not last. After the rate bottomed out at about 55,000 cases and 1,500 deaths per day in mid-March, some states — notably Michigan — began seeing an uptick.Since then, the national numbers have steadily risen. As of Saturday, the daily count was up to nearly 69,000, and the weekly average was 19 percent higher than the figure two weeks earlier.Even when cases were falling, researchers questioned the notion that vaccinations were the reason. Millions of Americans are immunized every day, but even now only 31 percent have received a single dose of a vaccine, and just 17 percent of the population have full protection, leaving a vast majority susceptible.“The fact is that we’re still in a position now where we don’t have enough vaccinated people,” said Kristian Andersen, a virologist at the Scripps Research in San Diego. “And if we, like Texas, say we’re done with Covid-19, B.1.1.7 will come in and remind us that we are not right. I have no doubt about it.”A nurse swabbed a patient for coronavirus infection at the Desmond Tutu HIV Foundation Youth Center in Masiphumelele, near Cape Town, South Africa.Joao Silva/The New York TimesVolunteers fumigated a senior citizen center in Soweto, South Africa, in February.Joao Silva/The New York TimesThe variant is particularly pervasive in Florida, where the state lifted restrictions and initially did not see a surge. Officials in other states cited this as a rationale for reopening. But now Florida’s infection rate is curving upward.The variant may only have been obscured by what scientists like to call seasonality. Respiratory infections are usually rare in Florida in the spring, noted Sarah Cobey, an evolutionary biologist at the University of Chicago. Coronavirus infections peaked in Florida last year in the summer, as heat drove people indoors, and may do so again.“I still don’t think we’re out of the woods,” Dr. Cobey said, referring to the country at large. “If we don’t have another wave this spring, then I’m going to be really, really worried about the fall.”While most vaccines are effective against B.1.1.7, researchers are increasingly concerned about other variants that contain a mutation called E484K. (Scientists often refer to it, appropriately, as “Eek.”)This mutation has evolved independently in many variants worldwide, suggesting that it offers the virus a powerful survival advantage.In laboratory studies, the Pfizer-BioNTech and Moderna vaccines seem to be slightly less effective against B.1.351, the variant identified in South Africa. That variant contains the Eek mutation, which seems to enable the virus to partly sidestep the body’s immune response. The vaccines made by Johnson & Johnson, AstraZeneca and Novavax were even less potent against B.1.351.“I think for the next year or two, E484K will be the most concerning” mutation, said Jesse Bloom, an evolutionary biologist at the Fred Hutchinson Cancer Research Center in Seattle.The mutation slightly alters the so-called spike protein sitting on the surface of the coronavirus, making it just a bit harder for antibodies to latch on and destroy the invader.The good news is that the virus seems to have just a few survival tricks in its bag, and that makes it easier for scientists to find and block those defenses. “I’m feeling pretty good about the fact that there aren’t that many choices,” said Michel Nussenzweig, an immunologist at Rockefeller University in New York.The Eek mutation seems to be the virus’s primary defense against the immune system. Researchers in South Africa recently reported that a new vaccine directed against B.1.351 ought to fend off all other variants, as well.Pfizer, BioNTech and Moderna already are testing newly designed booster shots against B.1.351 that should work against any variants known to blunt the immune response.Instead of a new vaccine against variants, however, it may be just as effective for Americans to receive a third dose of the Pfizer-BioNtech or Moderna vaccines in six months to a year, said Dr. Anthony S. Fauci, head of the National Institute of Allergy and Infectious Diseases.That would keep antibody levels high in each recipient, overwhelming any variant — a more practical strategy than making a specialized vaccine for each new variant that emerges, he said.“My only concern about chasing all the variants is that you’d almost be playing Whac-A-Mole, you know, because they’ll keep coming up and keep coming up,” Dr. Fauci said. In one form or another, the new coronavirus is here to stay, many scientists believe. Multiple variants may be circulating in the country at the same time, as is the case for common cold coronaviruses and influenza. Keeping them at bay may require an annual shot, like the flu vaccine.The best way to deter the emergence of dangerous variants is to keep cases down now and to immunize the vast majority of the world — not just the United States — as quickly as possible. If significant pockets of the globe remain unprotected, the virus will continue to evolve in dangerous new ways.“This might be something that we have to deal with for a long time,” said Rosalind Eggo, an epidemiologist at London School of Hygiene and Tropical Medicine.Still, she added, “Even if it changes again, which it is very likely to do, we are in a better, much stronger position than a year ago to deal with it.”

Read more →